Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

Recombinant IL23A (Risankizumab Biosimilar) antibody

This Human Monoclonal antibody specifically detects IL23A (Risankizumab Biosimilar) in FACS, BLI, ELISA, Func and SPR. It exhibits reactivity toward Human.
Catalog No. ABIN7676025
-15% Promotion 2026
$294.23
$346.15
save $51.92 (-15 %)
Plus shipping costs $50.00
Shipping to: United States
Delivery in 10 to 11 Business Days

Quick Overview for Recombinant IL23A (Risankizumab Biosimilar) antibody (ABIN7676025)

Target

IL23A (Risankizumab Biosimilar)

Antibody Type

Recombinant Antibody

Reactivity

Human

Host

  • 1
  • 1
Human

Clonality

  • 1
  • 1
Monoclonal

Conjugate

  • 2
This IL23A (Risankizumab Biosimilar) antibody is un-conjugated

Application

Flow Cytometry (FACS), Bio-Layer Interferometry (BLI), ELISA, Functional Studies (Func), Surface Plasmon Resonance (SPR)
  • Expression System

    CHO Cells

    Purpose

    Anti-IL-23a Reference Antibody (risankizumab)

    Sequence

    QVQLVQSGAE VKKPGSSVKV SCKASGYTFT DQTIHWMRQA PGQGLEWIGY IYPRDDSPKY NENFKGKVTI TADKSTSTAY MELSSLRSED TAVYYCAIPD RSGYAWFIYW GQGTLVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT YICNVNHKPS NTKVDKRVEP KSCDKTHTCP PCPAPEAAGG PSVFLFPPKP KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ VYTLPPSREE MTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPG,DIQMTQSPSS LSASVGDRVT ITCKASRDVA IAVAWYQQKP GKVPKLLIYW ASTRHTGVPS RFSGSGSRTD FTLTISSLQP EDVADYFCHQ YSSYPFTFGS GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC

    Characteristics

    Anti-IL-23a Reference Antibody (risankizumab) is expressed from CHO. The heavy chain type is huIgG1, and the light chain type is hukappa. It has a predicted MW of 145.5 kDa.

    Purity

    >95 %

    Isotype

    IgG1
  • Application Notes

    Optimal working dilution should be determined by the investigator.

    Comment

    Therapeutic Agents by Target and Mechanism: IL-23p19 inhibitors

    Restrictions

    For Research Use only
  • Format

    Lyophilized

    Concentration

    1 mg/mL

    Buffer

    25 mM histidine, 8 % sucrose, 0.01 % Tween80 pH 6.2

    Storage

    4 °C,-80 °C

    Storage Comment

    +4°C,-80°C
  • Target

    IL23A (Risankizumab Biosimilar)

    Alternative Name

    IL-23a (Risankizumab Biosimilar)

    Target Type

    Biosimilar

    Molecular Weight

    145.5 kDa

    UniProt

    Q9NPF7
You are here:
Chat with us!